Lilly’s Drops Peglispro Insulin; Now It Can Focus On Copycat Lantus
This article was originally published in The Pink Sheet Daily
Executive Summary
The company will cease development of the novel long-acting insulin for the treatment of diabetes after previously revealing safety concerns. Lilly will take a $55mn charge in the fourth quarter.
You may also be interested in...
Lilly and Boehringer Ingelheim Launch Biosimilar Lantus In UK, Germany
The cost of biosimilar Lantus to payers is at around a 15% discount to the originator product in the UK, but cost-savings are expected to vary across Europe as supply contracts with health insurers and hospitals are negotiated.
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.
CinFina Pushes Early Work In Obesity In Hopes Of A Deal
Emerging Company Profile: CinFina is advancing two novel mechanisms of action in obesity as monotherapies and in combination with GLP-1s.